- Home
- CRIS vs CODX Comparison
CRIS vs CODX Comparison
Compare CRIS & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- CODX
- Stock Information
- Founded
- CRIS 2000
- CODX 2013
- Country
- CRIS United States
- CODX United States
- Employees
- CRIS N/A
- CODX N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- CODX Medical/Dental Instruments
- Sector
- CRIS Health Care
- CODX Health Care
- Exchange
- CRIS Nasdaq
- CODX Nasdaq
- Market Cap
- CRIS 13.5M
- CODX 11.9M
- IPO Year
- CRIS 2000
- CODX 2017
- Fundamental
- Price
- CRIS $1.96
- CODX $0.34
- Analyst Decision
- CRIS Strong Buy
- CODX Buy
- Analyst Count
- CRIS 3
- CODX 2
- Target Price
- CRIS $21.00
- CODX $5.50
- AVG Volume (30 Days)
- CRIS 99.1K
- CODX 74.5K
- Earning Date
- CRIS 05-06-2025
- CODX 05-08-2025
- Dividend Yield
- CRIS N/A
- CODX N/A
- EPS Growth
- CRIS N/A
- CODX N/A
- EPS
- CRIS N/A
- CODX N/A
- Revenue
- CRIS $11,202,000.00
- CODX $3,497,583.00
- Revenue This Year
- CRIS $4.67
- CODX N/A
- Revenue Next Year
- CRIS $9.77
- CODX N/A
- P/E Ratio
- CRIS N/A
- CODX N/A
- Revenue Growth
- CRIS 14.17
- CODX N/A
- 52 Week Low
- CRIS $1.02
- CODX $0.28
- 52 Week High
- CRIS $16.93
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- CRIS 50.58
- CODX 42.07
- Support Level
- CRIS $1.85
- CODX $0.34
- Resistance Level
- CRIS $2.25
- CODX $0.37
- Average True Range (ATR)
- CRIS 0.27
- CODX 0.03
- MACD
- CRIS 0.04
- CODX 0.00
- Stochastic Oscillator
- CRIS 41.73
- CODX 19.33
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.